Zhejiang NHU Company (002001) Fair Value & Analysis
Healthcare · CN · Market cap 88.6B CNY
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 21 days ago
Fair value updated Jul 17, 2026, revised from ¥47.25 to ¥44.59 (−5.6%) since Jun 25, 2026. Share price +3.0% over the past month.
A solid business, screening 46% undervalued on our models.
What matters now
- The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (¥33.56). The market is more pessimistic than our downside scenario.
- A fairly wide model range (¥33.56 to ¥62.20) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range ¥13.37 – ¥38.27 · fair‑value band ¥33.56 – ¥62.20 · the ¥30.45 price screens below the ¥44.59 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Zhejiang NHU Company (002001) currently trades at ¥30.45, while our model-based Fair Value estimate is ¥44.59, implying the stock looks roughly 46.4% undervalued today. We read business quality at 74/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Zhejiang NHU Company generated revenue of 23.1B CNY at a net margin of 29.1%. Revenue grew 15.7% year over year. It earns a return on equity of 20.4%. The balance sheet holds a net cash position of 1.4B CNY. Fundamentals as of Jul 17, 2026
Our scenario range runs from ¥33.56 (bear case) to ¥62.20 (bull case); at ¥30.45, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high and 50% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 46%, 002001 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥56.88) versus Asset-Based (¥7.15). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 65
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhejiang NHU Company Ltd., together with its subsidiaries, produces and sells nutritional products, fragrances and flavors, polymer materials, and active pharmaceutical ingredients in China and internationally. It operates through Pharmaceutical and Chemical; and Other segments.
Full company description
Zhejiang NHU Company Ltd., together with its subsidiaries, produces and sells nutritional products, fragrances and flavors, polymer materials, and active pharmaceutical ingredients in China and internationally. It operates through Pharmaceutical and Chemical; and Other segments. The company offers animal nutrition products comprising vitamins, amino acids, and carotenoids for poultry, swine, ruminants, and farmed fish; human nutrition products consisting of vitamins A, D3, E, H, C, B5, B6, and B12, as well as coenzyme Q10, beta carotene, taurine, and l-serine for use in nutritional supplements, food and beverages, and personal care applications; and flavor and fragrance products, including fruity, floral, and green/herbal products for use in soap, toothpaste, shampoo, skin care products, and food and beverage products. It also provides pigments; methionine, biotin, cysteine, and tryptophan; linalool, citral, leaf alcohol, methyl dihydrojasmonate, raspberry ketone, privet aldehyde, and menthol; PPS and PPA resins, PPS fibers, LTF composite materials, and PPS cast films and heat pipes; chemical products, such as prenol, l-ascorbic acid, acrylic acid, acrolein, sodium thiomethoxide in H2O, acrolein cyanohydrin acetate, diethyl oxalate/oxalic acid diethyl ester, potassium sulfate, ammonium sulfate, isophorone, cyclopentanone, and isovaleraldehyde for use in construction chemicals, crop protection, fertilizers, industrial solvents, and intermediates. In addition, the company offers active pharmaceutical ingredients, vitamins, and pharmaceutical intermediates, as well as professional services for preparation companies. The company exports its products. The company was incorporated in 1999 and is headquartered in Xinchang, the People's Republic of China. Zhejiang NHU Company Ltd. operates as a subsidiary of NHU Holding Group Co.,Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang NHU Company reported revenue of ¥22.3B in FY2025 versus ¥14.9B in FY2021, a compound +10.5%/yr. Reported net income was ¥6.8B in FY2025, compounding +11.6%/yr from FY2021.
Watch 002001: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Zhejiang NHU Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhejiang NHU Company (002001) overvalued or undervalued?
What is the fair value of 002001?
What is the quality score of 002001?
What is the revenue of Zhejiang NHU Company (002001)?
What is the net profit margin of 002001?
Does Zhejiang NHU Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhejiang NHU Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.